US Edition
News from pharmaceutical-technology.com
Information about Pharmaceutical-technology.com
Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's WebsiteMedia Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmaceutical-technology.com News
Johnson & Johnson · United StatesDizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short appe…See the Story
With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short
71% Center coverage: 32 sources
China · ChinaJoincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assetsSee the Story
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
43% Left coverage: 14 sources
BusinessOffer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential...See the Story
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
50% Left coverage: 8 sources
Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars
67% Right coverage: 3 sources
